Rami Komrokji, MD

Articles

Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

August 24th 2022

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

Myelofibrosis Treatment Approaches after Disease Progression

August 18th 2022

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Clinical Scenario: A 67-Year-Old with Myelofibrosis

August 18th 2022

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

Management of Accelerated Phase Myeloproliferative Neoplasms

August 11th 2022

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

Novel Agents Under Investigation for Myelofibrosis

August 11th 2022

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

August 11th 2022

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

Efficacy and Safety of JAK Inhibitors for Myelofibrosis

August 11th 2022

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

New JAK Inhibitors in Myelofibrosis Treatment

August 3rd 2022

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

August 3rd 2022

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

Risk Stratification for Myelofibrosis

July 22nd 2022

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

Myeloproliferative Neoplasms: Myelofibrosis

July 22nd 2022

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

July 13th 2022

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

July 13th 2022

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

Treatment Options for Polycythemia Vera

July 6th 2022

An overview of the treatment options for patients with polycythemia vera.

Myeloproliferative Neoplasms: Polycythemia Vera

July 6th 2022

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Managing Patients with Essential Thrombocythemia

June 29th 2022

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Myeloproliferative Neoplasms: Essential Thrombocythemia

June 29th 2022

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

Unmet Needs in High-Risk MDS

August 27th 2021

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Promising Data for Pevonedistat in High-Risk MDS

August 27th 2021

Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.

Emerging Role of Venetoclax in the Treatment of MDS

August 27th 2021

Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.